All In Biotech

Drug Trial Radar · NCT04715750

Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity

An Open Label, Single Center Study to Evaluate the Safety and Imaging Characteristics of [18F]PI-2620 as PET Radioligand for Imaging Tau Deposition in the Brains of Patients With Mild to Moderate Alzheimer's Disease (AD) and Patients With Progressive Supranuclear Palsy (PSP) After i.v. Application of [18F]PI-2620 With High and Low Specific Activity

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Nov 12, 2020

Primary completion

Oct 26, 2022

Study completion Oct 26, 2022

Sponsor

Lead sponsor
Life Molecular Imaging GmbHIndustry
Sponsor type
Industry
Collaborators
Life Molecular Imaging SA.
First posted
Jan 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label study without randomisation. All eligible patients will receive two administrations of the investigational imaging agent \[18F\]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low specific activity (40-50 µg tracer mass dose).

Conditions

  • Alzheimer Disease
  • Progressive Supranuclear Palsy

Interventions

  • [18F]-PI2620Drug

    \[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low specific activity (40-50 µg tracer mass dose).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparability of visual assessment of PI-2620 tau PET images obtained after injection of high specific activity and low specific activity in AD and PSP patients.Time frame: 4-54 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Nuclear Medicine, University Hospital Leipzig

    Leipzig, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.